MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 113.17% | 76.64% | 62.51% | 80.42% | 82.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.77% | 38.61% | 22.00% | 30.90% | 99.26% |
| Operating Income | -2.77% | -38.61% | -22.00% | -30.90% | -99.26% |
| Income Before Tax | 1.52% | -41.55% | -19.16% | -22.41% | -93.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.52% | -41.55% | -19.16% | -22.41% | -93.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.52% | -41.55% | -19.16% | -22.41% | -93.56% |
| EBIT | -2.77% | -38.61% | -22.00% | -30.90% | -99.26% |
| EBITDA | -2.83% | -38.72% | -22.21% | -31.03% | -99.40% |
| EPS Basic | 29.35% | -5.36% | 77.30% | 95.40% | 93.03% |
| Normalized Basic EPS | 31.48% | -3.20% | 77.30% | 95.40% | 92.93% |
| EPS Diluted | 29.35% | -5.36% | 77.30% | 95.40% | 93.03% |
| Normalized Diluted EPS | 31.48% | -3.20% | 77.30% | 95.40% | 92.93% |
| Average Basic Shares Outstanding | 39.40% | 34.36% | 424.87% | 2,561.87% | 2,678.81% |
| Average Diluted Shares Outstanding | 39.40% | 34.36% | 424.87% | 2,561.87% | 2,678.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |